Cancer of the prostate.
暂无分享,去创建一个
Georg Bartsch | Carlo Greco | Gemma Gatta | Filippo de Braud | G. Bartsch | G. Gatta | F. D. De Braud | C. Greco | R. Valdagni | S. Bracarda | O. de Cobelli | Riccardo Valdagni | Sergio Bracarda | Ottavio de Cobelli | Tommaso Prayer-Galetti | T. Prayer-Galetti
[1] A. G. Tulloch,et al. The role of bone scanning in the assessment of prostatic carcinoma. , 1978, British journal of urology.
[2] J. Yarnold,et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] G. Haas,et al. The state of prostate cancer screening in the United States. , 1993, European urology.
[4] K. Wallner,et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.
[5] L. Einhorn,et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D A Meyers,et al. Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.
[7] M. Blute,et al. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. , 1995, The Journal of urology.
[8] M. Kattan,et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Bergstralh,et al. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. , 1993, Urology.
[10] D. Wood,et al. Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .
[11] Gibbons Rp. Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity. , 1988 .
[12] James D. Cox,et al. Consensus statement: Guidelines for PSA following radiation therapy , 1997 .
[13] A. Partin,et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.
[14] R. Sankila,et al. Survival of cancer patients in Finland 1955-1994. , 1999, Acta oncologica.
[15] D. Bostwick,et al. Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.
[16] M. Resnick,et al. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? , 2000, The Journal of urology.
[17] J. Hanley,et al. Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .
[18] P. Narayan,et al. Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .
[19] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[20] K. Wallner,et al. Impact of Transurethral Resection on the Long-Term Outcome of Patients with Prostatic Carcinoma , 1993 .
[21] Z. Petrovich,et al. The Role of Prostate-Specific Antigen in the Management of Prostate Cancer , 1996 .
[22] K. Pienta,et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. , 1997, Urology.
[23] U. Patel,et al. The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation. , 1994, British journal of urology.
[24] P. Walsh,et al. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. , 1991, The Journal of urology.
[25] H M Rosenberg,et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.
[26] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[27] M. Soloway,et al. Prognostic significance of changes in prostate‐specific markers after endocrine treatment of stage D2 prostatic cancer , 1992, Cancer.
[28] C. Catton,et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] D. Budman,et al. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. , 1999, Seminars in oncology.
[30] C C Ling,et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.
[31] P. Schellhammer,et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. , 1997, European urology.
[32] D. Bostwick,et al. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. , 1997, Human pathology.
[33] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.
[34] R. Sylvester,et al. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. , 1995, European urology.
[35] D. Wood,et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.
[36] T. Stamey,et al. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. , 2000, The Journal of urology.
[37] Scardino Pt. The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. , 2000 .
[38] J. Hugosson,et al. Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis. , 1996, British journal of urology.
[39] George Starkschall,et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.
[40] J. Siemiatycki,et al. Occupation and prostate cancer. , 2001, Epidemiologic reviews.
[41] C. Parker,et al. Salvage radiotherapy for PSA failure after radical prostatectomy. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] A. Haese*,et al. Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy. , 2002, European urology.
[43] S. Rosenthal,et al. RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate , 2000 .
[44] M. Coleman,et al. Survival of cancer patients in europe—The EUROCARE study , 1995, Cancer Causes & Control.
[45] P. Walsh,et al. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. , 1979, The Journal of urology.
[46] E. Small,et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Renshaw,et al. Expectant management of stage A‐1 (T1a) prostate cancer utilizing serum PSA levels: A preliminary report , 1999, Journal of surgical oncology.
[48] P. Walsh,et al. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. , 2000, Urology.
[49] M. Kattan,et al. Factors predicting recovery of erections after radical prostatectomy. , 2000, The Journal of urology.
[50] P Carlsson,et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. , 1990, BMJ.
[51] E. Feuer,et al. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.
[52] J. Manola,et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.
[53] F. Vicini,et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. , 1999, Urology.
[54] A. Zlotta,et al. Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. , 1996, European Urology.
[55] O. Bertetto,et al. Quality of life studies and genito-urinary tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] R. Vessella,et al. Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.
[57] M. Coleman,et al. Cancer prevalence in European registry areas. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] P. Kantoff,et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] F. Gilliland,et al. Male genital cancers , 1995, Cancer.
[60] J W Moul,et al. Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. , 2000, The Journal of urology.
[61] Crawford,et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.
[62] S. Fosså,et al. Does the service at a large oncologic out-patient clinic satisfy the patients' perceived need? , 1996, International journal of health care quality assurance.
[63] C. Roehrborn,et al. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. , 1996, Urology.
[64] B. Wullich,et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. , 2004, The Journal of urology.
[65] J. Blasko,et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. , 2002, Seminars in radiation oncology.
[66] M. Barry,et al. Patient-re ported complications and follow-up treatment after radical prostatectomy , 1993 .
[67] D. Heitjan,et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] D. Bostwick,et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. , 1996, The Journal of urology.
[69] W. Catalona,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.
[70] K-H. Kurth. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials: Prostate Cancer Trialists Collaborative Group , 2000 .
[71] Juni Palmgren,et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.
[72] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[73] P. Walsh,et al. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). , 1994, The Journal of urology.
[74] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[75] C G Chute,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.
[76] G. Coetzee,et al. Re: Prostate cancer and the androgen receptor. , 1994, Journal of the National Cancer Institute.
[77] A. McEwan,et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. , 1991, European journal of cancer.
[78] J. Goellner,et al. Prostate shape, external striated urethral sphincter and radical prostatectomy: the apical dissection. , 1987, The Journal of urology.
[79] S. Devesa,et al. International trends and patterns of prostate cancer incidence and mortality , 2000, International journal of cancer.
[80] Roberto Orecchia,et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[81] J. Bishoff,et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. , 1995, Urology.
[82] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[83] R. Huddart,et al. Spinal cord compression--what are the treatment standards? , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).
[84] L. Lacombe,et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. , 1999, The Journal of urology.
[85] John Calvin Reed,et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.
[86] W. Hop,et al. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. , 1998, The Journal of urology.
[87] M Goitein,et al. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. , 1993, International journal of radiation oncology, biology, physics.
[88] T. Stamey,et al. Making the most out of six systematic sextant biopsies. , 1995, Urology.
[89] P. Casale,et al. DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy. , 1996, European urology.
[90] J. Oesterling,et al. The Relationship Between Prostatic Intraepithelial Neoplasia and Prostate Cancer: Critical Issues , 1997 .
[91] Z. Petrovich,et al. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer , 2002, BJU international.
[92] M. Kattan,et al. Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.
[93] D. Bostwick,et al. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. , 1993, The Urologic clinics of North America.
[94] R. Kane,et al. The results of a five‐year early prostate cancer detection intervention , 1996, Cancer.
[95] E. Bergstralh,et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. , 2001, The Journal of urology.
[96] M. Terris,et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.
[97] D. Fryback,et al. Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.
[98] L. Denis,et al. Ketoconazole and liarozole in the treatment of advanced prostatic cancer , 1993, Cancer.
[99] R A Stephenson,et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.
[100] G. Hudes,et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. , 2001, Urology.
[101] H. Sandler,et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. , 1995, International journal of radiation oncology, biology, physics.
[102] J. Cummings,et al. Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. , 1996, The Journal of urology.
[103] D. Bostwick. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. , 1996, European urology.
[104] A. Haese*,et al. Early Prostate-Specific Antigen Relapse after Radical Retropubic Prostatectomy:Prediction on the Basis of Preoperative andPostoperative Tumor Characteristics , 1999, European Urology.
[105] L. Baert,et al. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view. , 1997, The Journal of urology.
[106] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[107] G. Jakse,et al. Evaluation of patients with diseases of the prostate using prostate-specific antigen density , 1995 .
[108] M. Coleman,et al. Toward a comparison of survival in American and European cancer patients , 2000, Cancer.
[109] R. Valicenti,et al. Radiation therapy after radical prostatectomy: a review of the issues and options. , 2003, Seminars in radiation oncology.
[110] E. Feuer,et al. Impact of screening on incidence and mortality of prostate cancer in the United States. , 2001, Epidemiologic reviews.
[111] J. Moul,et al. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer , 1991, Cancer.
[112] J. Epstein. Pathologic assessment of the surgical specimen. , 2001, The Urologic clinics of North America.
[113] S. Taneja,et al. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone‐refractory prostate carcinoma , 2001, Cancer.
[114] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] W. Catalona,et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. , 1999, The Journal of urology.
[116] A. Pantuck,et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.
[117] A. Whittemore,et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. , 1995, American journal of epidemiology.
[118] L. Vanuytsel,et al. Radical Prostatectomy Can Provide a Cure For Well–Selected Clinical Stage T3 Prostate Cancer , 2000, European Urology.
[119] E. Metter,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.
[120] Tumour suppressor genes in prostate cancer. , 1997, Seminars in cancer biology.
[121] F Berrino,et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[122] J. Oesterling,et al. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. , 1996, The Journal of urology.
[123] B. King,et al. Anatomy of radical prostatectomy as defined by magnetic resonance imaging. , 1998, The Journal of urology.
[124] G Starkschall,et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] G N Collins,et al. Multiple transrectal ultrasound-guided prostatic biopsies--true morbidity and patient acceptance. , 1993, British journal of urology.
[126] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[127] K. Pummer,et al. Postprostatectomy radiotherapy for high-risk prostate cancer. , 2002, Urology.
[128] J. Oesterling,et al. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. , 1994, Mayo Clinic proceedings.
[129] G. Chisholm,et al. Bone scanning and plasma phosphatases in carcinoma of the prostate. , 1978, British journal of urology.
[130] D. Grignon,et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.
[131] J. Blasko,et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. , 2002, International journal of radiation oncology, biology, physics.
[132] T E Schultheiss,et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.
[133] P. Walsh,et al. Relationship Between Perineural Tumor Invasion on Needle Biopsy and Radical Prostatectomy Capsular Penetration in Clinical Stage B Adenocarcinoma of the Prostate , 1993, The American journal of surgical pathology.
[134] M. Blute,et al. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. , 1998, The Journal of urology.
[135] C C Ling,et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[136] T. Stamey,et al. Nerve sparing radical prostatectomy: a different view. , 1995, The Journal of urology.
[137] J. Oesterling,et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.
[138] J. Hugosson,et al. Diagnosis of prostate cancer: optimal number of prostate biopsies related to serum prostate-specific antigen and findings on digital rectal examination. , 1997, Scandinavian journal of urology and nephrology.
[139] J. Hugosson,et al. Hormonal treatment before radical prostatectomy: a 3-year followup. , 1998, The Journal of urology.
[140] F. Nathan,et al. Antiandrogen withdrawal syndrome with nilutamide. , 1997, The Journal of urology.
[141] A. Zlotta,et al. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. , 1997, The Journal of urology.
[142] S. Litwin,et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] R. A. Jones,et al. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997, British journal of urology.
[144] L. Collette,et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. , 2004, The Journal of urology.
[145] D. Bostwick,et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.
[146] P. Hoskin,et al. Palliation of bone metastases. , 1991, European journal of cancer.
[147] William R. Fair,et al. DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .
[148] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[149] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[150] D. Dearnaley,et al. Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[151] O. Sartor,et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. , 1995, The American journal of medicine.
[152] F. Burkhard,et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? , 2003, The Journal of urology.
[153] H. Zincke. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. , 1989, Urology.
[154] P. Carroll,et al. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. , 1999, Urology.
[155] B. Guillonneau,et al. Laparoscopic radical prostatectomy: the Montsouris experience. , 2000, The Journal of urology.
[156] H. Huland,et al. Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy. , 1997, The Journal of urology.
[157] E. Small,et al. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer , 1995, Cancer.
[158] R. Thisted,et al. Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.
[159] U. Norming,et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. , 1992, The Journal of urology.
[160] J. Blasko,et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. , 2003, International journal of radiation oncology, biology, physics.
[161] F. Schröder,et al. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. , 1994, The Journal of urology.
[162] C. Brendler,et al. An analysis of watchful waiting for clinically localized prostate cancer. , 1998, The Journal of urology.
[163] D. Kuban,et al. Treatment of clinical local failure after radiation therapy for prostate carcinoma. , 1993, The Journal of urology.
[164] G. Hanks,et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.
[165] W. Catalona,et al. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.
[166] F. Mostofi,et al. Pathology of carcinoma of the prostate , 1992, Cancer.
[167] G. Chodak,et al. Early detection and screening for prostatic cancer. , 1989, Urology.
[168] G. Chodak,et al. Routine screening for cancer of the prostate. , 1991, Journal of the National Cancer Institute.
[169] D. Williams. The male genital tract , 1958 .
[170] G. Coetzee,et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk , 1995, Nature Medicine.
[171] T. Stamey,et al. Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.
[172] A. Zlotta,et al. 4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer , 2000, European Urology.
[173] R. Clements,et al. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer? , 1992, The British journal of radiology.
[174] W Cavanagh,et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[175] Jewett Hj. The present status of radical prostatectomy for stages A and B prostatic cancer. , 1975 .
[176] D. Kuban,et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. , 2001, International journal of radiation oncology, biology, physics.
[177] R H Brook,et al. Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.
[178] D. Bostwick,et al. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.
[179] R. Badalament,et al. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens , 1995, Cancer.
[180] A. Yagoda,et al. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.
[181] R. Oyen. Imaging Modalities in Diagnosis and Staging of Carcinoma of the Prostate , 1996 .
[182] D. Paulson,et al. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? , 2004, World Journal of Urology.
[183] W. Ellis,et al. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. , 1994, The Journal of urology.
[184] E. Bergstralh,et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. , 2000, The Journal of urology.